William DeVinney

Briglia Hundley P.C.
Of Counsel

William DeVinney has a broad litigation practice that includes antitrust, intellectual property, employment, securities and other complex commercial litigation. He has extensive trial experience, both as a member of trial teams and as first chair in jury and bench trials, arbitrations proceedings, and regulatory hearings, and has argued cases before several federal and state appellate courts.

Mr. DeVinney also counsels clients about complying with antitrust, privacy, and employment laws, as well as regulatory risks arising from mergers, distributions, licensing, franchise, sales, and other agreements.

Articles

287 Bulletin

Bryan R. Dunlap, Richard Liebeskind, William DeVinney The US FTC employs an uncommon remedy to resolve the anticompetitive concerns of a merger-to-monopoly by requiring the merged firm to license a generic form of its breakthrough cancer pain drug to a third party (Cephalon / CIMA)

160

In two recent decisions involving pharmaceutical mergers – Cephalon/Cima, in August 2004, and Genzyme/Novazyme, in January 2004, a divided Federal Trade Commission was accused by dissenting Commissioners of breaking with precedent and allowing acquisitions involving innovator pharmaceuticals (...)

Bryan R. Dunlap, Richard Liebeskind, William DeVinney The US FTC requires divestiture of three brand drugs in order to grant approval to a merger between two pharmaceutical companies (Sanofi-Synthelabo / Aventis)

127

In two recent decisions involving pharmaceutical mergers – Cephalon/Cima, in August 2004, and Genzyme/Novazyme, in January 2004, a divided Federal Trade Commission was accused by dissenting Commissioners of breaking with precedent and allowing acquisitions involving innovator pharmaceuticals (...)

Send a message